D.E. Shaw & Co’s Rocket Pharmaceuticals RCKT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.77M | Sell |
2,169,625
-470,893
| -18% | -$1.87M | ﹤0.01% | 1828 |
|
|
2025
Q4 | $9.27M | Buy |
2,640,518
+450,768
| +21% | +$1.54M | 0.01% | 1823 |
|
|
2025
Q3 | $7.14M | Buy |
2,189,750
+1,196,925
| +121% | +$3.77M | ﹤0.01% | 1928 |
|
|
2025
Q2 | $2.43M | Buy |
+992,825
| New | +$5.03M | ﹤0.01% | 2598 |
|
|
2023
Q3 | – | Sell |
-42,215
| Closed | -$839K | – | 4444 |
|
|
2023
Q2 | $839K | Sell |
42,215
-43,530
| -51% | -$879K | ﹤0.01% | 3184 |
|
|
2023
Q1 | $1.47M | Sell |
85,745
-96,417
| -53% | -$1.89M | ﹤0.01% | 2898 |
|
|
2022
Q4 | $3.56M | Sell |
182,162
-266,180
| -59% | -$4.9M | ﹤0.01% | 2404 |
|
|
2022
Q3 | $7.16M | Buy |
448,342
+260,041
| +138% | +$4.06M | 0.01% | 1696 |
|
|
2022
Q2 | $2.59M | Sell |
188,301
-3,211
| -2% | -$38.3K | ﹤0.01% | 2835 |
|
|
2022
Q1 | $3.04M | Buy |
191,512
+40,018
| +26% | +$691K | ﹤0.01% | 2872 |
|
|
2021
Q4 | $3.31M | Sell |
151,494
-33,940
| -18% | -$926K | ﹤0.01% | 2841 |
|
|
2021
Q3 | $5.54M | Sell |
185,434
-14,584
| -7% | -$531K | 0.01% | 2019 |
|
|
2021
Q2 | $8.86M | Sell |
200,018
-106,232
| -35% | -$4.61M | 0.01% | 1593 |
|
|
2021
Q1 | $13.6M | Sell |
306,250
-12,388
| -4% | -$680K | 0.01% | 1168 |
|
|
2020
Q4 | $17.5M | Buy |
318,638
+98,759
| +45% | +$3.6M | 0.02% | 1030 |
|
|
2020
Q3 | $5.03M | Sell |
219,879
-6,323
| -3% | -$156K | 0.01% | 1684 |
|
|
2020
Q2 | $4.73M | Buy |
226,202
+18,799
| +9% | +$339K | 0.01% | 1692 |
|
|
2020
Q1 | $2.89M | Buy |
207,403
+188,976
| +1,026% | +$3.74M | ﹤0.01% | 1886 |
|
|
2019
Q4 | $419K | Buy |
+18,427
| New | +$308K | ﹤0.01% | 3484 |
|
|
2019
Q1 | – | Sell |
-11,166
| Closed | -$165K | – | 3871 |
|
|
2018
Q4 | $165K | Sell |
11,166
-13,890
| -55% | -$231K | ﹤0.01% | 3583 |
|
|
2018
Q3 | $617K | Sell |
25,056
-32,694
| -57% | -$709K | ﹤0.01% | 2991 |
|
|
2018
Q2 | $1.13M | Sell |
57,750
-81,450
| -59% | -$1.54M | ﹤0.01% | 2627 |
|
|
2018
Q1 | $2.61M | Buy |
139,200
+14,127
| +11% | +$230K | ﹤0.01% | 1858 |
|
|
2017
Q4 | $1.31M | Buy |
125,073
+90,042
| +257% | +$893K | ﹤0.01% | 2423 |
|
|
2017
Q3 | $249K | Buy |
35,031
+14,340
| +69% | +$65.5K | ﹤0.01% | 3211 |
|
|
2017
Q2 | $157K | Sell |
20,691
-3,782
| -15% | -$28.2K | ﹤0.01% | 3226 |
|
|
2017
Q1 | $196K | Sell |
24,473
-1,384
| -5% | -$9.31K | ﹤0.01% | 3132 |
|
|
2016
Q4 | $631K | Sell |
25,857
-24,799
| -49% | -$708K | ﹤0.01% | 2725 |
|
|
2016
Q3 | $1.92M | Buy |
50,656
+14,969
| +42% | +$471K | ﹤0.01% | 1963 |
|
|
2016
Q2 | $1.06M | Buy |
35,687
+27,476
| +335% | +$966K | ﹤0.01% | 2380 |
|
|
2016
Q1 | $243K | Buy |
8,211
+4,550
| +124% | +$137K | ﹤0.01% | 3112 |
|
|
2015
Q4 | $166K | Buy |
+3,661
| New | +$160K | ﹤0.01% | 3606 |
|
Other funds holding RCKT
RI
VPM
VCM
MC
NM
N
D.E. Shaw & Co's RCKT Position: Q1 2026 in Review
D.E. Shaw & Co reduced its Rocket Pharmaceuticals (RCKT) stake by 18% in Q1 2026, selling an estimated $1.87M and leaving 2,169,625 shares worth $7.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1828.
D.E. Shaw & Co first reported a position in RCKT in Q4 2015 and has held it in 32 quarters since. The position peaked at $17.5M in Q4 2020. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.
- D.E. Shaw & Co held 2,169,625 shares of Rocket Pharmaceuticals worth $7.77M as of Q1 2026.
- D.E. Shaw & Co sold 470,893 Rocket Pharmaceuticals shares in Q1 2026, an estimated $1.87M.
- Rocket Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1828 holding.
- D.E. Shaw & Co first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 32 quarters since.
- D.E. Shaw & Co's Rocket Pharmaceuticals position peaked at $17.5M in Q4 2020.
- 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.